U.S., Nov. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07224373) titled 'An Open-label Study of AZD0120 in Adults With Multiple Sclerosis' on Oct. 21.
Brief Summary: This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with Multiple Sclerosis.
Study Start Date: Dec. 23
Study Type: INTERVENTIONAL
Condition:
Multiple Sclerosis
Intervention:
BIOLOGICAL: AZD0120 - Regimen 1
Regimen 1, infusion of AZD0120
BIOLOGICAL: AZD0120 - Regimen 2
Regimen 2, infusion of AZD0120
Recruitment Status: NOT_YET_RECRUITING
Sponsor: AstraZeneca
Published by HT Digital Content Service...